美国医疗系统中医疗保健相关感染的预防：利用肠道微生物群对抗感染。
PREVENTION OF HEALTH CARE-ASSOCIATED INFECTIONS IN U.S. HEALTH SYSTEMS: HARNESSING THE GUT MICROBIOME TO COMBAT INFECTION.
作者信息
Safdar Nasia
机构信息
Madison, WI.
出版信息
Trans Am Clin Climatol Assoc. 2025;135:260-268.
Abstract
Health care-associated infections (HAIs) remain a major challenge in the U.S. health care system, with ( or ) being the most prevalent. The use of antibiotics disrupts the gut microbiota, predisposing individuals to infection. Recent research has highlighted the role of the gut microbiome in preventing and treating infections (CDI). Strategies such as fecal microbiota transplantation (FMT) and live biotherapeutic products (LBPs) offer promising alternatives to conventional antibiotic treatments. This paper explores the mechanisms underlying CDI, the role of the gut microbiome in infection prevention, and innovative therapeutic approaches.
摘要
医疗保健相关感染（HAIs）在美国医疗保健系统中仍然是一项重大挑战，其中艰难梭菌感染（CDI）最为普遍。抗生素的使用会破坏肠道微生物群，使个体易受感染。最近的研究突出了肠道微生物群在预防和治疗艰难梭菌感染中的作用。粪便微生物群移植（FMT）和活生物治疗产品（LBPs）等策略为传统抗生素治疗提供了有前景的替代方案。本文探讨了艰难梭菌感染的潜在机制、肠道微生物群在感染预防中的作用以及创新治疗方法。
相似文献
1
PREVENTION OF HEALTH CARE-ASSOCIATED INFECTIONS IN U.S. HEALTH SYSTEMS: HARNESSING THE GUT MICROBIOME TO COMBAT INFECTION.
Trans Am Clin Climatol Assoc. 2025;135:260-268.
2
The evolving landscape of live biotherapeutics in the treatment of Clostridioides difficile infection.
Indian J Gastroenterol. 2025 Apr;44(2):129-141. doi: 10.1007/s12664-024-01717-9. Epub 2025 Jan 16.
3
Human microbiome: Impact of newly approved treatments on C. difficile infection.
Am J Health Syst Pharm. 2025 Feb 10;82(4):174-183. doi: 10.1093/ajhp/zxae249.
4
Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).
Cochrane Database Syst Rev. 2023 Apr 25;4(4):CD013871. doi: 10.1002/14651858.CD013871.pub2.
5
Host origin of microbiota drives functional recovery and clearance in mice.
mBio. 2025 Jun 2:e0110825. doi: 10.1128/mbio.01108-25.
6
Fecal microbiota live - jslm (Rebyota™/RBL) for management of recurrent infection.
Future Microbiol. 2024;19(14):1243-1251. doi: 10.1080/17460913.2024.2364583. Epub 2024 Jul 11.
7
Dietary iron attenuates infection via modulation of intestinal immune response and gut microbiota.
Virulence. 2025 Dec;16(1):2529454. doi: 10.1080/21505594.2025.2529454. Epub 2025 Jul 16.
8
Safety and Tolerability of CP101, a Full-Spectrum, Oral Microbiome Therapeutic for the Prevention of Recurrent Clostridioides difficile Infection: A Phase 2 Randomized Controlled Trial.
Gastroenterology. 2025 Feb;168(2):357-366.e3. doi: 10.1053/j.gastro.2024.09.030. Epub 2024 Oct 2.
9
Faecal microbiota transplantation for recurrent Clostridiodes difficile infection & its global regulatory landscape.
Indian J Med Res. 2025 Feb;161(2):113-119. doi: 10.25259/IJMR_818_2024.
10
Importance of underlying mechanisms for interpreting relative risk of Clostridioides difficile infection among antibiotic-exposed patients in healthcare facilities.
PLoS One. 2024 Aug 8;19(8):e0306622. doi: 10.1371/journal.pone.0306622. eCollection 2024.
本文引用的文献
1
Incidence and Risk Factors of Clostridium difficile Infection Among Adult Patients Admitted to the Inpatient Department of a Tertiary Care Hospital: A Hospital-Based Observational Study.
Cureus. 2024 Dec 3;16(12):e75071. doi: 10.7759/cureus.75071. eCollection 2024 Dec.
2
Therapeutics involved in managing initial and recurrent infection: An updated literature review.
World J Gastrointest Pharmacol Ther. 2024 Sep 5;15(5):95467. doi: 10.4292/wjgpt.v15.i5.95467.
3
Elucidating human gut microbiota interactions that robustly inhibit diverse Clostridioides difficile strains across different nutrient landscapes.
Nat Commun. 2024 Aug 28;15(1):7416. doi: 10.1038/s41467-024-51062-w.
4
Efficacy of Fecal Microbiota (REBYOTA) in Recurrent Clostridium difficile Infections: A Systematic Review and Meta-Analysis.
Cureus. 2024 Apr 23;16(4):e58862. doi: 10.7759/cureus.58862. eCollection 2024 Apr.
5
SER-109, an Oral Microbiome Therapy for Recurrent Infection.
N Engl J Med. 2022 Jan 20;386(3):220-229. doi: 10.1056/NEJMoa2106516.
6
A Review of Clostridioides difficile Infection and Antibiotic-Associated Diarrhea.
Gastroenterol Clin North Am. 2021 Jun;50(2):323-340. doi: 10.1016/j.gtc.2021.02.010.
7
The Interplay between the Gut Microbiome and the Immune System in the Context of Infectious Diseases throughout Life and the Role of Nutrition in Optimizing Treatment Strategies.
Nutrients. 2021 Mar 9;13(3):886. doi: 10.3390/nu13030886.
8
Clostridioides difficile Infection in the Stem Cell Transplant and Hematologic Malignancy Population.
Infect Dis Clin North Am. 2019 Jun;33(2):447-466. doi: 10.1016/j.idc.2019.02.010.
9
The Gut Microbiota Is Associated with Clearance of Clostridium difficile Infection Independent of Adaptive Immunity.
mSphere. 2019 Jan 30;4(1):e00698-18. doi: 10.1128/mSphereDirect.00698-18.
10
Outcomes of Community and Healthcare-onset Clostridium difficile Infections.
Clin Infect Dis. 2019 Apr 8;68(8):1343-1350. doi: 10.1093/cid/ciy715.
Zotero 插件